Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood

Overview of attention for article published in Journal of Neuroimmunology, November 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

patent: 6 patents
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 59 Dimensions

Readers on

mendeley: 54 Mendeley

Summary News X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 1 news story.

Ravulizumab Showed Preclinical Promise for ALS. What Happened?

MedPage Today, 11 Sep 2023

Neurology > General Neurology Phase III trial terminated for futility by Judy George, Deputy Managing Editor, MedPage Today…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.